Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study.
COVID-19
SARS-CoV-2
long-term care facilities
older people
omicron
vaccine effectiveness
Journal
Age and ageing
ISSN: 1468-2834
Titre abrégé: Age Ageing
Pays: England
ID NLM: 0375655
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
received:
09
03
2023
medline:
21
8
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused severe disease in unvaccinated long-term care facility (LTCF) residents. Initial booster vaccination following primary vaccination is known to provide strong short-term protection, but data are limited on duration of protection and the protective effect of further booster vaccinations. To evaluate the effectiveness of third, fourth and fifth dose booster vaccination against SARS-CoV-2 related mortality amongst older residents of LTCFs. Prospective cohort study. LTCFs for older people in England participating in the VIVALDI study. Residents aged >65 years at participating LTCFs were eligible for inclusion if they had at least one polymerase chain reaction or lateral flow device result within the analysis period 1 January 2022 to 31 December 2022. We excluded individuals who had not received at least two vaccine doses before the analysis period. Cox regression was used to estimate relative hazards of SARS-CoV-2 related mortality following 1-3 booster vaccinations compared with primary vaccination, stratified by previous SARS-CoV-2 infection and adjusting for age, sex and LTCF size (total beds). A total of 13,407 residents were included. Our results indicate that third, fourth and fifth dose booster vaccination provide additional short-term protection against SARS-CoV-2 related mortality relative to primary vaccination, with consistent stabilisation beyond 112 days to 45-75% reduction in risk relative to primary vaccination. Successive booster vaccination doses provide additional short-term protection against SARS-CoV-2 related mortality amongst older LTCF residents. However, we did not find evidence of a longer-term reduction in risk beyond that provided by initial booster vaccination.
Sections du résumé
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused severe disease in unvaccinated long-term care facility (LTCF) residents. Initial booster vaccination following primary vaccination is known to provide strong short-term protection, but data are limited on duration of protection and the protective effect of further booster vaccinations.
OBJECTIVE
To evaluate the effectiveness of third, fourth and fifth dose booster vaccination against SARS-CoV-2 related mortality amongst older residents of LTCFs.
DESIGN
Prospective cohort study.
SETTING
LTCFs for older people in England participating in the VIVALDI study.
METHODS
Residents aged >65 years at participating LTCFs were eligible for inclusion if they had at least one polymerase chain reaction or lateral flow device result within the analysis period 1 January 2022 to 31 December 2022. We excluded individuals who had not received at least two vaccine doses before the analysis period. Cox regression was used to estimate relative hazards of SARS-CoV-2 related mortality following 1-3 booster vaccinations compared with primary vaccination, stratified by previous SARS-CoV-2 infection and adjusting for age, sex and LTCF size (total beds).
RESULTS
A total of 13,407 residents were included. Our results indicate that third, fourth and fifth dose booster vaccination provide additional short-term protection against SARS-CoV-2 related mortality relative to primary vaccination, with consistent stabilisation beyond 112 days to 45-75% reduction in risk relative to primary vaccination.
CONCLUSIONS
Successive booster vaccination doses provide additional short-term protection against SARS-CoV-2 related mortality amongst older LTCF residents. However, we did not find evidence of a longer-term reduction in risk beyond that provided by initial booster vaccination.
Identifiants
pubmed: 37595069
pii: 7241725
doi: 10.1093/ageing/afad141
pmc: PMC10438206
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
ID : 222907/Z/21/Z
Pays : United Kingdom
Organisme : Department of Health
ID : CS-2016-007
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Chief Scientist Office
Pays : United Kingdom
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Geriatrics Society.
Références
Lancet Infect Dis. 2023 May;23(5):556-567
pubmed: 36681084
J Infect Dis. 2023 Apr 18;227(8):977-980
pubmed: 36461711
Lancet Healthy Longev. 2022 Jul;3(7):e470-e480
pubmed: 35813279
Lancet Healthy Longev. 2022 Jan;3(1):e13-e21
pubmed: 34935001
N Engl J Med. 2023 Feb 9;388(6):481-483
pubmed: 36630616
MMWR Morb Mortal Wkly Rep. 2022 Dec 02;71(48):1526-1530
pubmed: 36454688
Sociol Health Illn. 2021 Aug;43(7):1614-1626
pubmed: 34255866
Wellcome Open Res. 2020 Oct 7;5:232
pubmed: 33564722
Int J Epidemiol. 2022 Jan 6;50(6):1804-1813
pubmed: 34999883
Open Forum Infect Dis. 2022 Dec 29;10(1):ofac694
pubmed: 36713473
BMJ. 2022 Jul 6;378:e071502
pubmed: 35793826
MMWR Morb Mortal Wkly Rep. 2022 Sep 30;71(39):1235-1238
pubmed: 36173757